The mere mention of the term “comparative effectiveness” evokes a host of reactions among pharmaceutical manufacturers: confusion, skepticism, even fear. With President Obama calling for a national agency for comparative effectiveness, no one doubts that it is coming to healthcare—but what will it encompass? How will comparative effectiveness impact access to medications? What can manufacturers do to prepare?

Join us on Thursday, June 25 at 2:00 PM (EDT), as Tommy Bramley, senior director for Xcenda, and Tracy Foster, president for Lash Group, present insights that address:

• An overview of comparative effectiveness and an update of its
  progress at the federal level
• Perspectives about comparative effectiveness from managed
  care stakeholders
• How manufacturers can evaluate their risk and prepare for additional
  requests for comparative analysis data
• What manufacturers can do to ensure continued patient access
  to products
• How manufacturers can validate ongoing clinical and economic
  benefits for their products

Register for this FREE Webcast!